Case Report: Infectious prophylaxis in hematological malignancies

Patients with hematological malignancies and past serological evidence of hepatitis B are at risk for HBV reactivation. In myeloproliferative neoplasms, continuous treatment with the JAK 1/2 inhibitor ruxolitinib confers a moderate risk of reactivation (1-10%); nevertheless, no prospective randomize...

Descripción completa

Detalles Bibliográficos
Autores principales: Passucci, Mauro, Masucci, Chiara, Paoletti, Francesca, Ielo, Claudia, Costa, Alessandro, Carmosino, Ida, Scalzulli, Emilia, Martelli, Maurizio, Gentile, Giuseppe, Breccia, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183604/
https://www.ncbi.nlm.nih.gov/pubmed/37197426
http://dx.doi.org/10.3389/fonc.2023.1163175

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183604/
https://www.ncbi.nlm.nih.gov/pubmed/37197426
http://dx.doi.org/10.3389/fonc.2023.1163175

Ejemplares similares